Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
14
self-reported 11–50 band
Founded
2014
12 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
1
Post IPO equity · Apr 2014 · US$ 3.0M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
PRESCIENT THERAPEUTICS LIMITED
ABN56006569106
Legal entities
Show as table · Prescient Therapeutics: 1 registry entity
| PRESCIENT THERAPEUTICS LIMITED | ABN 56006569106 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Prescient’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt.
Targeted therapy:
Prescient’s first in class targeted therapy – PTX-100 – is currently in clinical development and showing encouraging activity in diseases of unmet need.
Cell therapies:
Prescient owns the exclusive rights to two next-generation cell therapy platform technologies, OmniCAR and CellPryme – both with the potential to enhance CAR-T therapies and overcome challenges faced by current generation approaches
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AULevel 11, 385 Bourke Street; Suite 2; Melbourne, Victoria 3205Primary
Grid intelligence Members
Funding
Last round · 24 April 2014US$ 3.0MPost IPO equity
Rounds1
Round typePost IPO equity · secondary transaction
Amount (USD)3,000,000
Stage rank6
Investors named0
Since last round11 yr 8 mo
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 2014 to 2026 |
| Post IPO equity · 24 Apr 2014 | US$ 3.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Prescient Therapeutics?
One Victoria entity on the ABR. PRESCIENT THERAPEUTICS LIMITED (ABN 56 006 569 106), high confidence.
How many people work at Prescient Therapeutics?
The record holds 14 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Prescient Therapeutics have offices?
One address on record, Australia only. Primary: Level 11, 385 Bourke Street, Suite 2, Melbourne, Victoria 3205.
Has Prescient Therapeutics raised funding?
One round. Latest 24 April 2014: post IPO equity, US$3,000,000.
Which companies are listed alongside Prescient Therapeutics?
29 profiles list Prescient Therapeutics as a peer — 96th percentile in Biotechnology Research. It lists ten peers of its own. Myrio Tx and INOVIQ Ltd (ASX:IIQ) list it back.